HIV vaccines: lessons learned and the way forward
JH Kim, S Rerks-Ngarm, JL Excler… - Current Opinion in HIV …, 2010 - journals.lww.com
JH Kim, S Rerks-Ngarm, JL Excler, NL Michael
Current Opinion in HIV and AIDS, 2010•journals.lww.comFuture HIV vaccine trials should define the RV144 immune responses relevant to protection,
improve durability and level of protection, and assess efficacy in diverse risk groups. New
strategies examining heterologous vector prime–boost, universal inserts, replicating vectors,
and novel protein or adjuvant immunogens should be explored to induce T-cell and
antibody responses. HIV vaccine development requires innovative ideas and a sustained
long-term commitment of scientists, governments, and the community.
improve durability and level of protection, and assess efficacy in diverse risk groups. New
strategies examining heterologous vector prime–boost, universal inserts, replicating vectors,
and novel protein or adjuvant immunogens should be explored to induce T-cell and
antibody responses. HIV vaccine development requires innovative ideas and a sustained
long-term commitment of scientists, governments, and the community.
Summary
Future HIV vaccine trials should define the RV144 immune responses relevant to protection, improve durability and level of protection, and assess efficacy in diverse risk groups. New strategies examining heterologous vector prime–boost, universal inserts, replicating vectors, and novel protein or adjuvant immunogens should be explored to induce T-cell and antibody responses. HIV vaccine development requires innovative ideas and a sustained long-term commitment of scientists, governments, and the community.
Lippincott Williams & Wilkins